PolyMedix, Inc. Company Profile
PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of serious acute cardiovascular disorders and infectious diseases. PolyMedix uses a rational drug design approach to create non-peptide small molecule drug candidates and polymers that mimic the activity of proteins. PMX-60056, PolyMedixâs lead heptagonist compound, is being developed to reverse the anticoagulant activity of both heparin and low molecular weight heparins. PolyMedix believes that PMX-60056 could potentially be a safer and easier to use anticoagulant reversing agent, with broader activity, than the currently approved therapy for reversing heparin. PMX-30063, PolyMedixâs lead antibiotic compound, is a small molecule that mimics human host-defense proteins and has a mechanism of action distinct from those of current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. PolyMedix plans to develop this compound for serious systemic Staphylococcal infections, including MRSA. Both PMX-60056 heptagonist and PMX-30063 antibiotic are undergoing clinical testing. PolyMedix also plans to continue the development of its PolyCidesâ¢, polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. For more information, please visit our website at www.polymedix.com.
News Articles
PolyMedix and University of Pennsylvania Collaborate to Develop New Class of Defensin-Mimetic ...
PolyMedix Receives Second Phase of NIH Grant for Up to $3 million
PolyMedix proposes $25 million follow-on
PolyMedix Inc. (OTCBB:PYMX) proposed to raise $25 million in a follow-on underwritten by Aegis Capital; Fordham Financial Management; and Emerging Growth Equities. PolyMedix, which made the announceme...
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf of investors w...
PolyMedix Announces Successful Meeting With FDA for Brilacidin
RADNOR, Pa., Nov. 16, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company dedicated to developing novel treatments for infectious diseases with defensin-mimetic antimicrobi...
PolyMedix Announces Departure of CEO, Appointment of Interim CEO
RADNOR, Pa., Jan. 30, 2013 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company dedicated to developing novel treatments for infectious diseases with defensin-mimetic antimicrobi...
PolyMedix CEO Posts Letter to Shareholders on Its Website
RADNOR, Pa., Feb. 7, 2013 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs based on its novel defensin-mimetic technology p...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of serious acute cardiovascular disorders and inf...
PolyMedix is the leader in developing biomimetics - novel small molecule, oligomer and polymer protein-mimetic drugs for membrane protein and protein:protein targets. PolyMedix has a proven computatio...
PolyMedix is a publicly traded emerging biotechnology company focused the development of novel drugs and biomaterials for the treatment of infectious diseases and acute c...
More Information about "PolyMedix, Inc." on BioPortfolio
We have published hundreds of PolyMedix, Inc. news stories on BioPortfolio along with dozens of PolyMedix, Inc. Clinical Trials and PubMed Articles about PolyMedix, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PolyMedix, Inc. Companies in our database. You can also find out about relevant PolyMedix, Inc. Drugs and Medications on this site too.
